CasX start-up Scribe Therapeutics raises $100 million for CRISPR therapies
Chemical & Engineering News
|
March 31, 2021
X min read
Chemical & Engineering News
|
March 31, 2021
Share on Social
More like this
News
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
May 21, 2026
Read Now
Press
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
May 21, 2026
Read Now
News
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
May 18, 2026
Read Now
Press
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
May 18, 2026
Read Now
News
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
April 30, 2026
Read Now
Press
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
April 30, 2026
Read Now
